Clinical trial • Phase I • Oncology
LY3200882 for Metastatic cancer | Solid tumor
Phase I trial of LY3200882 for Metastatic cancer | Solid tumor. 1 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Metastatic cancer | Solid tumor
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 16-02-2024
- First CTIS Authorization Date
- 27-02-2024
Eligibility
Recruits 1 Vulnerable population selected; no details on consent or assent handling available in the record..
- Vulnerable Population
- Vulnerable population selected; no details on consent or assent handling available in the record.
Recruitment
- Recruitment Window Months
- 93
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 1
Spain
- Earliest CTIS Part Ii Submission Date
- 03-01-2024
- Latest Decision Or Authorization Date
- 12-04-2024
- Processing Time Days
- 100
- Number Of Sites
- 1
- Number Of Participants
- 1
Sites
- Site Name
- Hospital Universitari Vall D Hebron
- Department Name
- Oncology
- Principal Investigator Name
- Maria Vieito Villar
- Principal Investigator Email
- mvieito@vhio.net
- Contact Person Name
- Maria Vieito Villar
- Contact Person Email
- mvieito@vhio.net
- Number Of Participants
- 1
Sponsor
Primary sponsor
- Full Name
- Eli Lilly & Co.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- LY3200882
Related trials
Other published trials that may interest you.
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
- Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)